评估甲硝唑作为健康成人CYP2A6新型安全表型探针
本研究在16名健康非吸烟成人中开展随机交叉药代动力学研究,比较甲硝唑500mg与尼古丁口香糖2mg,评估血浆2HM/MTZ与3HC/COT比值的相关性。结果显示两者在多个时间点相关性≥0.9(P<0.001),CYP2A6基因型显著影响表型比值,甲硝唑组无不良事件报告。
要点
- 甲硝唑500mg后血浆2HM/MTZ与3HC/COT在多个时间点相关性≥0.9。
- CYP2A6基因型显著影响MTZ和NIC表型比值,弱代谢者比值显著降低。
- 甲硝唑组无不良事件,尼古丁组38%(n=6)报告轻度不良事件。
核心结论
- 甲硝唑通过2HM/MTZ比值在健康成人中表现良好,可作为CYP2A6新型安全表型探针。
研究设计与样本
- 随机交叉药代动力学研究,纳入16名健康非吸烟成人,洗脱期至少2周,分别给予甲硝唑500mg和尼古丁口香糖2mg,血浆采样分别为48小时和8小时。
主要发现
- 血浆2HM/MTZ与3HC/COT比值在多个时间点相关性≥0.9(P<0.001)。
- CYP2A6基因型显著影响MTZ和NIC表型比值,弱代谢预测表型者2HM/MTZ比值≤58%、3HC/COT比值≤56%,与强代谢预测表型者相比在所有检测时间点P<0.05。
- 甲硝唑组无不良事件报告,尼古丁组38%(n=6)报告轻度不良事件。
关键数值与推荐
- 甲硝唑500mg给药后48小时内多个时间点2HM/MTZ与3HC/COT相关性≥0.9(P<0.001)。
- 弱代谢预测表型者2HM/MTZ比值≤58%、3HC/COT比值≤56%(与强代谢预测表型者相比,P<0.05)。
临床怎么用
- 甲硝唑可作为CYP2A6表型探针,给药后48小时内多个时间点可查询2HM/MTZ比值。
- 解读2HM/MTZ比值时需结合CYP2A6基因型,弱代谢者比值显著降低。
局限性
- 研究样本量较小(16名健康非吸烟成人),结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: CYP2A6 is a genetically polymorphic enzyme resulting in differential substrate metabolism and health behaviours. Current phenotyping probes for CYP2A6 exhibit limitations related to procurement (deuterated cotinine), toxicity (coumarin), specificity (caffeine) and age-appropriate administration (nicotine, NIC). In vitro, CYP2A6 selectively forms 2-hydroxymetronidazole (2HM) from metronidazole (MTZ). The purpose of this study was to evaluate MTZ as a CYP2A6 phenotyping probe drug in healthy adults against the well-established method of measuring trans-3-hydroxycotinine (3HC)/cotinine (COT). METHODS: A randomized, cross-over, pharmacokinetic study was completed in 16 healthy, nonsmoking adults. Separated by a washout period of at least 2 weeks, MTZ 500 mg and NIC gum 2 mg were administered and plasma was sampled over 48 hours and 8 hours, respectively. Correlations of plasma metabolite/parent ratios (2HM/MTZ; 3HC/COT) were assessed by Pearson coefficient. CYP2A6 genotyping was conducted and incorporated as a variable of plasma ratio response. RESULTS: Correlations between the plasma ratio 2HM/MTZ and 3HC/COT were ≥ 0.9 at multiple time points (P < 0.001), demonstrating a wide window during which 2HM/MTZ can be queried post-MTZ dose. CYP2A6 genotype had significant impacts on both MTZ and NIC phenotyping ratios with decreased activity predicted phenotypes demonstrating 2HM/MTZ ratios ≤58% and 3HC/COT ratios ≤56% compared with extensive activity predicted phenotypes at all time points examined in the study (P < 0.05). No adverse events were reported in the MTZ arm while 38% (n = 6) of participants reported mild adverse events in the NIC arm. CONCLUSIONS: Metronidazole via 2HM/MTZ performed well as a novel, safe phenotyping probe for CYP2A6 in healthy adults.
引用
- Stancil SL, Pearce RE, Tyndale RF, et al. Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. Br J Clin Pharmacol. 2019. PMID: 30706508. doi:10.1111/bcp.13884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。